Alpha 2.0
Login Register
» Authors » Kazuhiro Mikagi

Kazuhiro Mikagi

Explore the profile of Kazuhiro Mikagi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 128
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Hisafumi Kinoshita
Ryuichi Kawahara
Hiroto Ishikawa
Masaki Tateishi
Yoshiyuki Wada
Hiroyuki Horiuchi
Tomoki Ryu
Yuko Takami
Hideki Saitsu
Yoshinobu Okabe
Published In
Gan To Kagaku Ryoho
Onco Targets Ther
Surg Today
Kurume Med J
Hepatol Int
Affiliations
Soon will be listed here.
Recent Articles
1.
[A Case of Laparoscopic Hepatectomy and Combined Resection of Lymph Nodes and Ureter for Liver Metastasis after Colorectal Cancer Surgery, with Local Lymph Node Recurrence and Bilateral Hydronephrosis]
Sato T, Sakai H, Goto Y, Kojima S, Nomura Y, Nakayama G, et al.
Gan To Kagaku Ryoho . 2019 Jun; 46(4):751-753. PMID: 31164524
A 65-year-old man with sigmoid colon cancer underwent sigmoidectomy, followed by 8 courses of oral S-1 as postoperative adjuvant chemotherapy. Three years and 3 months after surgery, the patient developed...
2.
Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation
Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al.
Hepatol Int . 2018 Mar; 12(2):149-157. PMID: 29488056
Background And Aim: The effects of achieving sustained virological response (SVR) on recurrence and survival after curative treatment in patients with hepatitis virus C (HCV)-related hepatocellular carcinoma (HCC) is unclear....
3.
Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A
Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Mikagi K, et al.
J Gastrointest Surg . 2017 Mar; 21(6):957-966. PMID: 28299619
The prognostic implications of the expression patterns of three tumor markers, alpha-fetoprotein (AFP), the Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxy prothrombin (DCP), have been evaluated in patients...
4.
Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism
Ryu T, Takami Y, Tsutsumi N, Tateishi M, Mikagi K, Wada Y, et al.
Surg Today . 2016 Sep; 47(5):548-554. PMID: 27577937
Purpose: To establish the efficacy and safety of simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy (Lap-Sp) for the treatment of hepatocellular carcinoma (HCC) with cirrhotic hypersplenism. Methods: Seventeen patients...
5.
Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases
Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H
Onco Targets Ther . 2016 Mar; 9:937-43. PMID: 26955286
Background: Five or more colorectal liver metastases (CRLM) are considered marginally resectable and cannot be treated solely by hepatic resection (Hr). This study investigated the long-term effectiveness of surgical treatment...
6.
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, Wada Y, et al.
Hepatol Int . 2016 Feb; 10(5):799-806. PMID: 26846471
Background: Because the recurrence rate of hepatocellular carcinoma (HCC) is high, even after curative treatments such as hepatic resection and microwave ablation, chemopreventive agents that can effectively suppress HCC recurrence...
7.
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma
Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H
PLoS One . 2016 Jan; 11(1):e0146456. PMID: 26745625
Background: Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear. We investigated the efficacy of sorafenib treatment...
8.
Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients
Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H
Onco Targets Ther . 2015 Nov; 8:3193-202. PMID: 26586953
Background: Sorafenib therapy improves survival in unresectable hepatocellular carcinoma (HCC) patients without an objective response. The present study investigated whether the initial imaging response might be a prognostic indicator after...
9.
Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma
Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, et al.
Case Rep Gastroenterol . 2015 Sep; 9(2):285-90. PMID: 26351418
Sorafenib is an effective treatment for unresectable hepatocellular carcinoma (HCC) characterized by disease stabilization. However, the response rates are very low (<9%percnt;), and a complete response is rarely achieved. We...
10.
Carcinosarcoma of the gallbladder: report of a case
Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Momosaki S, et al.
Clin J Gastroenterol . 2015 Jul; 7(5):455-9. PMID: 26184028
Carcinosarcoma is a rare neoplasm with epithelial and mesenchymal components. We herein report the case of a 68-year-old male with a carcinosarcoma of the gallbladder. Preoperative examinations revealed the gallbladder...